The U.S. Department of Health and Human Services Office of the Chief Technology Officer and the American Society of Nephrology have selected 15 winning teams for Phase I of the KidneyX Redesign Dialysis prize competition.
John R. Sedor , MD, FASN was appointed chair of the KidneyX Steering Committee. Dr. Sedor will be a leader in sparking innovation and encouraging investment for the prevention, diagnosis and treatment of kidney disease.
According to HHS Deputy Secretary Eric Hargan, HHS wants to shift Medicare payment policies to encourage providers to shift dialysis to patients' homes, which would save money on treating end-stage renal disease.
KidneyX recently announced it has closed the application period for the first phase of its Redesign Dialysis competition after receiving 165 submissions.
HHS Secretary Alex Azar on Monday told a crowd of kidney disease patients and advocates the Trump administration is overhauling Medicare's payment system to move the bulk of dialysis treatments from clinics to the home.
Dialysis is a therapy whose time has come, and disruptive innovation is needed. In a first-of-its-kind partnership between the US Department of Health and Human Services and the American Society of Nephrology, the ongoing KidneyX: Redesign Dialysis prize competition is looking to spur innovation that completely disrupts the way kidney failure is treated.
The American Society of Nephrology's "Technology Roadmap for Innovative Approaches to Renal Replacement Therapy" aims to spark new ideas about how to treat kidney disease beyond dialysis. The roadmap lays out specific goals for therapy improvements, suggested time horizons, and the kinds of multidisciplinary collaborations required to make those improvements happen.
The Department of Health and Human Services and the American Society of Nephrology launched a $2.65 million challenge to seek better treatments for kidney disease. The program, called the KidneyX Innovation Accelerator, was launched at the American Society of Nephrology's annual meeting in San Diego.
In the fight against kidney disease, this is our moment as a community to look beyond the status quo and cynics and imagine the possible. The time is now to say "If not us, then who? And if not now, then when?"
Mark D. Okusa, MD, FASN, President of the American Society of Nephrology, catalogues the need for innovation in nephrology and the potential of KidneyX to accelerate the development and commercialization of kidney therapeutics and improve the lives of patients with kidney diseases.
There are no upcoming events at this time.
